Assessing public economic gains from expanding HPV vaccination in Portugal: a governmental perspective analysis
Expanding HPV vaccination to adult populations up to 26 years of age likely offers additional economic gains that exceed expenditures when compared to the current vaccination strategy, translating public health benefits of vaccination strategies into macroeconomic and fiscal outcomes for Portugal.
Authors
- Mark P. Connolly (ORCID: https://orcid.org/0000-0002-1886-745X)
- Nikolaos Kotsopoulos (ORCID: https://orcid.org/0000-0002-8248-7697)
- Andrew Pavelyev
- Joana Silva (ORCID: https://orcid.org/0000-0003-0121-517X)
- Ugne Sabale
- Bernardo Rodrigues
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of Groningen (NL)
- National and Kapodistrian University of Athens (GR)
- MSD (Lithuania) (LT)
- Public Health Solutions (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2026-01-29
- DOI
- https://doi.org/10.1080/13696998.2026.2617010
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00